Ona Therapeutics raises €30M in Series A financing

  • Breakthrough approach to developing first-in-class treatments for metastatic cancer patients
  • Financing to progress lead candidate to proof of clinical efficacy
  • Supported by strong European investor syndicate including Alta Life Sciences, Asabys Partners, Bpifrance – InnoBio 2, Fund+ and Ysios Capital

Barcelona, Spain, June 16th 2020: Ona Therapeutics, which is focused on the discovery and development of therapeutic biologics to treat metastatic cancer, announces today the closing of a €30 million Series A financing, with participation from existing investor Asabys Partners and new investors Alta Life Sciences, Bpifrance – InnoBio 2, Fund+ and Ysios Capital.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH